JP2017533969A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017533969A5 JP2017533969A5 JP2017544552A JP2017544552A JP2017533969A5 JP 2017533969 A5 JP2017533969 A5 JP 2017533969A5 JP 2017544552 A JP2017544552 A JP 2017544552A JP 2017544552 A JP2017544552 A JP 2017544552A JP 2017533969 A5 JP2017533969 A5 JP 2017533969A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic
- naca
- agent according
- prophylactic agent
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462076594P | 2014-11-07 | 2014-11-07 | |
| US62/076,594 | 2014-11-07 | ||
| PCT/US2015/059589 WO2016073931A1 (en) | 2014-11-07 | 2015-11-06 | Treatment of retinitis pigmentosa with n-acetylcysteine amide |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019191044A Division JP2020023549A (ja) | 2014-11-07 | 2019-10-18 | Ｎ−アセチルシステインアミドによる網膜色素変性症の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017533969A JP2017533969A (ja) | 2017-11-16 |
| JP2017533969A5 true JP2017533969A5 (https=) | 2018-04-19 |
Family
ID=55909913
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017544552A Pending JP2017533969A (ja) | 2014-11-07 | 2015-11-06 | Ｎ−アセチルシステインアミドによる網膜色素変性症の治療 |
| JP2019191044A Pending JP2020023549A (ja) | 2014-11-07 | 2019-10-18 | Ｎ−アセチルシステインアミドによる網膜色素変性症の治療 |
| JP2021147283A Pending JP2021193119A (ja) | 2014-11-07 | 2021-09-10 | Ｎ−アセチルシステインアミドによる網膜色素変性症の治療 |
| JP2023127716A Pending JP2023145734A (ja) | 2014-11-07 | 2023-08-04 | Ｎ－アセチルシステインアミドによる網膜色素変性症の治療 |
| JP2025126989A Pending JP2025160381A (ja) | 2014-11-07 | 2025-07-30 | Ｎ－アセチルシステインアミドによる網膜色素変性症の治療 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019191044A Pending JP2020023549A (ja) | 2014-11-07 | 2019-10-18 | Ｎ−アセチルシステインアミドによる網膜色素変性症の治療 |
| JP2021147283A Pending JP2021193119A (ja) | 2014-11-07 | 2021-09-10 | Ｎ−アセチルシステインアミドによる網膜色素変性症の治療 |
| JP2023127716A Pending JP2023145734A (ja) | 2014-11-07 | 2023-08-04 | Ｎ－アセチルシステインアミドによる網膜色素変性症の治療 |
| JP2025126989A Pending JP2025160381A (ja) | 2014-11-07 | 2025-07-30 | Ｎ－アセチルシステインアミドによる網膜色素変性症の治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20180296503A1 (https=) |
| EP (2) | EP4000612A1 (https=) |
| JP (5) | JP2017533969A (https=) |
| KR (3) | KR20230152177A (https=) |
| CN (2) | CN107426997A (https=) |
| AU (5) | AU2015342831B2 (https=) |
| BR (1) | BR112017009584A2 (https=) |
| CA (1) | CA2967327C (https=) |
| HK (1) | HK1252822A1 (https=) |
| RU (1) | RU2711913C2 (https=) |
| WO (2) | WO2016073829A2 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10752593B2 (en) | 2018-12-28 | 2020-08-25 | Endogena Therapeutics, Inc. | Compounds for use as therapeutically active substances in the treatment of retinal diseases |
| BR112017009584A2 (pt) | 2014-11-07 | 2017-12-26 | Nacuity Pharmaceuticals Inc | tratamento de retinite pigmentosa com n-acetilcisteína amida |
| US11268964B2 (en) | 2014-11-11 | 2022-03-08 | The Johns Hopkins University | Biomarkers useful in the treatment of subjects having diseases of the eye |
| US11548851B2 (en) | 2017-09-20 | 2023-01-10 | Nacuity Pharmaceuticals, Inc. | Method for preparation of n-acetyl cysteine amide and derivatives thereof |
| CN111386255B (zh) | 2017-09-20 | 2021-11-23 | 纳崔泰制药有限公司 | 用于制备n-乙酰基半胱氨酸酰胺及其衍生物的方法 |
| US11091433B2 (en) | 2017-09-20 | 2021-08-17 | Nacuity Pharmaceutials, Inc. | Method for preparation of N-acetyl cysteine amide and derivatives thereof |
| US20190135741A1 (en) * | 2017-11-09 | 2019-05-09 | Nacuity Pharmaceuticals, Inc. | Methods of Making Deuterium-Enriched N-acetylcysteine Amide (D-NACA) and (2R, 2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress |
| US20190151271A1 (en) * | 2017-11-21 | 2019-05-23 | The Johns Hopkins University | Compositions and methods for treatment of eye diseases |
| EP3823671B1 (en) * | 2018-07-09 | 2024-02-07 | Fondation Asile Des Aveugles | Inhibition of prc2 subunits to treat eye disorders |
| CN109096161B (zh) * | 2018-08-24 | 2020-10-27 | 武汉远大弘元股份有限公司 | 一种n-乙酰半胱氨酸的制备方法 |
| US10807973B2 (en) | 2018-12-28 | 2020-10-20 | Endogena Therapeutics, Inc. | Compounds for use as therapeutically active substances in the treatment of retinal diseases |
| EP3908341A4 (en) | 2019-01-11 | 2022-03-02 | NaCuity Pharmaceuticals, Inc. | TREATMENT OF AGE-RELATED MACULAR DEGENERATION, GLAUCOMA AND DIABETIC RETINOPATHY WITH N-ACETYLCYSTEINE AMIDE (NACA) OR (2R,2R')-3,3'-BIS(2-ACETAMIDOPROPANAMIDE) DISULFANEDIYL (DINACA) |
| US12458608B2 (en) | 2019-01-11 | 2025-11-04 | Nacuity Pharmaceuticals, Inc. | N-Acetylcysteine Amide (NACA) and (2R,2R′)-3,3′ disulfanediyl BIS(2-acetamidopropanamide) (DINACA) for the prevention and treatment of radiation dermatitis and skin lightening, skin whitening and skin improvement |
| WO2020146660A1 (en) | 2019-01-11 | 2020-07-16 | Nacuity Pharmaceuticals, Inc. | N-acetylcysteine amide (naca) and (2r,2r')-3-3'-disulfanediyl bis (2-acetamidopropanamide) (dinaca) for prevention and treatment of radiation pneumonitis and treatment of pulmonary function in cystic fibrosis |
| CA3167959A1 (en) * | 2020-01-24 | 2021-07-29 | Nacuity Pharmaceuticals, Inc. | Prodrug for the treatment of disease and injury of oxidative stress |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3340147A (en) | 1965-06-28 | 1967-09-05 | Mead Johnson & Co | Amides of n-acylated cysteines |
| US6420429B1 (en) | 1997-12-23 | 2002-07-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Brain targeted low molecular weight hydrophobic antioxidant compounds |
| US5874468A (en) | 1996-12-26 | 1999-02-23 | Yissum | Brain targeted low molecular weight hydrophobic antioxidant compounds |
| AU2002345699A1 (en) | 2001-06-13 | 2002-12-23 | Webb-Waring Institute For Biomedical Research | A diagnostic and prognostic method for evaluating ocular inflammation and oxidative stress and the treatment of the same |
| BE1014949A3 (fr) | 2001-08-14 | 2004-07-06 | Probiox | Procede de detection de stress oxydant et trousse pour sa mise en oeuvre. |
| AU2003247144B2 (en) | 2002-08-02 | 2007-11-29 | Mor Research Applications Ltd. | Treatment of multiple sclerosis with brain targeted anti oxidant compounds |
| EP1551399A4 (en) | 2002-09-30 | 2011-01-05 | Mark A Babizhayev | METHOD FOR THE TOPICAL TREATMENT OF EYE DISEASES AND COMPOSITION AND DEVICE FOR THIS TREATMENT |
| JP2005350405A (ja) | 2004-06-11 | 2005-12-22 | Shiseido Co Ltd | 重合抑制剤および即時型黒化防止用皮膚外用剤 |
| US20090234011A1 (en) * | 2005-04-21 | 2009-09-17 | Goldstein Glenn A | N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress |
| CN101232877A (zh) * | 2005-04-21 | 2008-07-30 | 格伦·A·戈尔茨坦 | 治疗与氧化应激有关的疾病和病症的n-乙酰半胱氨酸酰胺（nac酰胺） |
| US8993627B2 (en) | 2005-04-21 | 2015-03-31 | Sentient Lifesciences, Inc. | N-acetylcysteine amide (NAC amide) for the treatment of diseases and conditions associated with oxidative stress |
| JP4840804B2 (ja) | 2006-01-20 | 2011-12-21 | 学校法人慶應義塾 | 酸化ストレスの判定方法 |
| CA2741954A1 (en) | 2008-10-29 | 2010-05-06 | Pacific Therapeutics Ltd. | Composition and method for treating fibrosis |
| US20120150029A1 (en) | 2008-12-19 | 2012-06-14 | University Of Miami | System and Method for Detection and Monitoring of Ocular Diseases and Disorders using Optical Coherence Tomography |
| US9173423B2 (en) | 2009-07-31 | 2015-11-03 | The Iams Company | Animal food kibble with electrostatically adhered dusting |
| WO2011044230A2 (en) | 2009-10-06 | 2011-04-14 | Goldstein Glenn A | N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions |
| EP2397125A1 (en) | 2010-06-15 | 2011-12-21 | Histocell, S.L. | Antioxidant composition |
| US20120142550A1 (en) | 2010-12-06 | 2012-06-07 | Zehnder James L | Vanin 1 as a Peripheral Blood Oxidative Stress Sensor |
| WO2013138744A1 (en) | 2012-03-16 | 2013-09-19 | M. Alphabet 1, Llc | Compositions for the treatment of skin disorders |
| CA2871774C (en) * | 2012-04-26 | 2021-05-18 | Sentient Lifesciences, Inc. | Use of n-acetylcysteine amide in the treatment of disease and injury |
| JP2016506391A (ja) | 2012-12-06 | 2016-03-03 | ステルス ペプチドズ インターナショナル インコーポレイテッド | ペプチド治療薬およびその使用方法 |
| WO2014100361A1 (en) | 2012-12-19 | 2014-06-26 | The Johns Hopkins University | Protection from oxidative damage by gene transfer by glutamate cysteine ligase and glutathione synthase |
| EP3122342B1 (en) | 2014-03-28 | 2020-09-23 | NaCuity Pharmaceuticals, Inc. | Method for the preparation of n-acetyl cysteine amide |
| BR112017009584A2 (pt) | 2014-11-07 | 2017-12-26 | Nacuity Pharmaceuticals Inc | tratamento de retinite pigmentosa com n-acetilcisteína amida |
| US11268964B2 (en) | 2014-11-11 | 2022-03-08 | The Johns Hopkins University | Biomarkers useful in the treatment of subjects having diseases of the eye |
| CA3017797A1 (en) | 2016-03-17 | 2017-09-21 | Thiogenesis Therapeutics, Inc. | Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders |
| CA3076392A1 (en) | 2017-09-20 | 2019-03-28 | Thiogenesis Therapeutics, Inc. | Methods for the treatment of cysteamine sensitive disorders |
| CN111386255B (zh) | 2017-09-20 | 2021-11-23 | 纳崔泰制药有限公司 | 用于制备n-乙酰基半胱氨酸酰胺及其衍生物的方法 |
| US20200253867A1 (en) | 2017-09-22 | 2020-08-13 | University Of Florida Research Foundation | Devices and methods for reducing cystine crystals in vivo |
| US20190135741A1 (en) | 2017-11-09 | 2019-05-09 | Nacuity Pharmaceuticals, Inc. | Methods of Making Deuterium-Enriched N-acetylcysteine Amide (D-NACA) and (2R, 2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress |
| US20200281944A1 (en) | 2017-11-17 | 2020-09-10 | Mahmood Piraee | Combinations Of Lanosterol Or 25-Hydroxycholesterol Including Derivatives Thereof Useful In The Treatment Of Lens Disorders |
| US20190151271A1 (en) | 2017-11-21 | 2019-05-23 | The Johns Hopkins University | Compositions and methods for treatment of eye diseases |
| CN108618993B (zh) | 2018-07-16 | 2021-07-27 | 广东格烯生物科技股份有限公司 | 一种美白组合物及其制备方法和应用 |
| US12599577B2 (en) | 2018-11-16 | 2026-04-14 | University of Pittsburgh—of the Commonwealth System of Higher Education | Thermoresponsive gel eye drop for ocular delivery of cysteamine |
| US12458608B2 (en) | 2019-01-11 | 2025-11-04 | Nacuity Pharmaceuticals, Inc. | N-Acetylcysteine Amide (NACA) and (2R,2R′)-3,3′ disulfanediyl BIS(2-acetamidopropanamide) (DINACA) for the prevention and treatment of radiation dermatitis and skin lightening, skin whitening and skin improvement |
| EP3908341A4 (en) | 2019-01-11 | 2022-03-02 | NaCuity Pharmaceuticals, Inc. | TREATMENT OF AGE-RELATED MACULAR DEGENERATION, GLAUCOMA AND DIABETIC RETINOPATHY WITH N-ACETYLCYSTEINE AMIDE (NACA) OR (2R,2R')-3,3'-BIS(2-ACETAMIDOPROPANAMIDE) DISULFANEDIYL (DINACA) |
| WO2020146660A1 (en) | 2019-01-11 | 2020-07-16 | Nacuity Pharmaceuticals, Inc. | N-acetylcysteine amide (naca) and (2r,2r')-3-3'-disulfanediyl bis (2-acetamidopropanamide) (dinaca) for prevention and treatment of radiation pneumonitis and treatment of pulmonary function in cystic fibrosis |
-
2015
- 2015-11-06 BR BR112017009584A patent/BR112017009584A2/pt not_active Application Discontinuation
- 2015-11-06 WO PCT/US2015/059418 patent/WO2016073829A2/en not_active Ceased
- 2015-11-06 EP EP21217485.8A patent/EP4000612A1/en active Pending
- 2015-11-06 KR KR1020237036499A patent/KR20230152177A/ko not_active Ceased
- 2015-11-06 KR KR1020227009489A patent/KR20220039853A/ko not_active Ceased
- 2015-11-06 JP JP2017544552A patent/JP2017533969A/ja active Pending
- 2015-11-06 CN CN201580072224.6A patent/CN107426997A/zh active Pending
- 2015-11-06 RU RU2017119230A patent/RU2711913C2/ru active
- 2015-11-06 EP EP15857309.7A patent/EP3214934A4/en not_active Ceased
- 2015-11-06 CN CN201810698779.7A patent/CN108498495A/zh active Pending
- 2015-11-06 US US15/524,636 patent/US20180296503A1/en not_active Abandoned
- 2015-11-06 US US15/523,665 patent/US12472157B2/en active Active
- 2015-11-06 KR KR1020177015227A patent/KR20170109527A/ko not_active Ceased
- 2015-11-06 CA CA2967327A patent/CA2967327C/en active Active
- 2015-11-06 WO PCT/US2015/059589 patent/WO2016073931A1/en not_active Ceased
- 2015-11-06 AU AU2015342831A patent/AU2015342831B2/en active Active
-
2018
- 2018-09-20 HK HK18112150.1A patent/HK1252822A1/zh unknown
-
2019
- 2019-10-18 JP JP2019191044A patent/JP2020023549A/ja active Pending
- 2019-11-07 AU AU2019261762A patent/AU2019261762B2/en active Active
-
2021
- 2021-09-06 AU AU2021225263A patent/AU2021225263B2/en active Active
- 2021-09-10 JP JP2021147283A patent/JP2021193119A/ja active Pending
-
2023
- 2023-08-04 JP JP2023127716A patent/JP2023145734A/ja active Pending
-
2024
- 2024-01-24 AU AU2024200436A patent/AU2024200436A1/en not_active Abandoned
-
2025
- 2025-07-30 JP JP2025126989A patent/JP2025160381A/ja active Pending
-
2026
- 2026-01-05 AU AU2026200033A patent/AU2026200033A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017533969A5 (https=) | ||
| JP2020023549A5 (https=) | ||
| JP2023145734A5 (https=) | ||
| RU2017119230A (ru) | Лечение пигментной дистрофии сетчатки n-ацетилцистеинамидом | |
| NZ605888A (en) | Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain | |
| HRP20220902T3 (hr) | Pripravci i njihova upotreba u liječenju multiple skleroze | |
| MX2020014000A (es) | Formulaciones en lámina que contienen dexmedetomidina y métodos para producirlas. | |
| RU2009148288A (ru) | Профилактическое или терапевтическое средство для возрастной дегенерации желтого пятна | |
| NZ595467A (en) | Sublingual pharmaceutical composition comprising a neutral oil | |
| IN2014MN01706A (https=) | ||
| AU2012284627A8 (en) | Method for manufacturing a pharmaceutical composition in the form of extended-release tablets containing Pirfenidone and use thereof in the regression of chronic renal insufficiency, breast capsular contracture and hepatic fibrosis in humans | |
| HRP20192133T1 (hr) | Kemijski spoj koristan kao posrednik za pripremu inhibitora katekol-o-metiltransferaze | |
| WO2015183963A3 (en) | Therapeutic compositions including redox-active parabenzoquinones and uses thereof | |
| JP2015038135A5 (https=) | ||
| JP2022518174A5 (https=) | ||
| RU2010147287A (ru) | Комбинированная композиция | |
| JP2017506624A5 (https=) | ||
| MX2021010106A (es) | Inhibidores de la via de respuesta al estres integrada. | |
| MX2010003441A (es) | Formulaciones galenicas de alisquireno y valsartan. | |
| PL2205279T3 (pl) | Farmaceutyczna kombinacja aliskirenu i walsartanu | |
| ME02474B (me) | Terapijski režimi | |
| MX2010007281A (es) | Composiciones farmaceuticas de amlodipina y valsartan. | |
| RU2020123405A (ru) | Лекарственная композиция для профилактики или лечения вторичного гиперпаратиреоза при поддерживающем диализе | |
| NZ751972A (en) | Treatment of prurigo nodularis | |
| HRP20190211T1 (hr) | Inhibitor proteina za prijenos kolesterilestera (cetp) i farmaceutski pripravci koji sadrže spomenuti inhibitor za primjenu u liječenju ili prevenciji kardiovaskularnih bolesti |